Bristol-Myers Squibb (BMY) Tops Q1 EPS by 2c, Offers Guidance
Bristol-Myers Squibb (NYSE: BMY) reported Q1 EPS of $1.96, $0.02 better than the analyst estimate of $1.94. Revenue for the quarter came in at $11.65 billion versus the consensus estimate of $11.42 billion.
GUIDANCE:
Bristol-Myers Squibb sees FY2022 EPS of $7.44-$7.74, versus the consensus of $7.73.
ey 2022 GAAP and non-GAAP line-item guidance assumptions are:
| U.S. GAAP | Non-GAAP
| ||
February (Prior) | April (Revised) | February (Prior) | April (Revised) | |
Total Net Sales | ~$47.0 billion or low single-digit increase | In-line with 2021 | ~$47.0 billion or low single-digit increase | In-line with 2021 |
Recent LOE Products1 | ~$10.5 billion or double-digit decline | ~$10.0 billion or double-digit decline | ~$10.5 billion or double-digit decline | ~$10.0 billion or double-digit decline |
Revlimid | $9.5-$10 billion | $9.0-$9.5 billion | $9.5-$10 billion | $9.0-$9.5 billion |
In-line Products & New Product Portfolio | ~$36.5 billion or Low double-digit increase | No Change | ~$36.5 billion or Low double-digit increase | No Change |
Gross Margin % | ~78% | No Change | ~78% | No Change |
Operating Expenses2 | Approx. 10% decline | Mid single-digit decline | In-line with 2021 | Low single-digit decline |
Tax Rate | ~24% | ~22% | ~16.5% | No Change |
Diluted EPS | $3.37-$3.67 | $2.92-$3.22 | $7.65 - $7.95 | $7.44 - $.7.743 |
For earnings history and earnings-related data on Bristol-Myers Squibb (BMY) click here.